Mavatar Launches Rare Disease Discovery Award
- New initiative to support research where data is scarce
Mavatar, a global specialist in AI- and data-driven precision medicine solutions, today announced the launch of the Mavatar Rare Disease Discovery Award 2026. This global initiative serves to support data-driven exploration of disease biology and drug development.
The awards will be granted quarterly throughout 2026, enabling scientists across disciplines and geographies to apply advanced analytical methods to some of the most challenging and underserved areas in biomedical research.
“Rare disease research is driven by clinical urgency but often limited by access to the right tools,” said Danuta Gawel, Chief Research & Development Officer at Mavatar. With this initiative, we want to empower researchers working in low-resource environments with scalable, AI-powered technology that can accelerate discovery even where traditional data is limited.”
The initiative builds on Mavatar’s growing presence in the rare disease space, including a recently announced non-clinical research collaboration with global biopharma company Sobi, focused on exploring IFNγ-related pathways using Mavatar Discovery. This partnership reinforces Mavatar’s commitment to enabling data-driven breakthroughs in complex and underserved disease areas.
Supporting discovery where data is limited
Rare diseases affect more than 300 million people worldwide, yet research efforts are often hindered by fragmented datasets, small patient cohorts, and limited access to advanced tools. Mavatar Discovery addresses these challenges by transforming large-scale transcriptomic data into structured, biologically meaningful insights, supporting hypothesis generation, target discovery, biomarker research, and mechanistic exploration in a reproducible and transparent way.
“Alongside our broader efforts to engage the life science community around data-driven precision medicine, we also want to lower barriers to advanced analytics in areas of high unmet need,” said Danuta Gawel.
“The Rare Disease Discovery Awards are one way we’re helping democratize access to data-driven tools that can drive real-world scientific progress.”
What the award includes
Each award recipient will receive:
- A full-access, one-year license to Mavatar Discovery
- Unlimited exploration of disease- and tissue-specific integrated transcriptomic datasets
- Access to analytical tools supporting target discovery, biomarker identification, cross-disease comparisons, and hypothesis generation
- Complimentary onboarding and scientific support from the Mavatar team
The award is open to researchers working in fields such as:
- Genetic and metabolic disorders
- Immunological and inflammatory diseases
- Rare cancers and pediatric conditions
- Other under-researched or low-prevalence diseases
How to apply
Researchers can register their interest at: Apply here
For more information contact:
Linda Wakeham
Chife Marketing & Communication Officer
linda.wakeham@mavatar.com
Mavatar is a global specialist in AI-and data-driven precision medicine solutions for all diseases. Built on over 20 years of scientific research, Mavatar’s proprietary DINA (Deep Integrated Network Analysis) framework powers two flagship platforms: Mavatar Discovery for accelerating disease and drug research, and Mavatar Precision for delivering personalized treatment recommendations in clinical care. By creating digital twins of both patients and diseases, Mavatar enables data-driven decisions that improve treatment outcomes, optimize clinical trials, and reduce healthcare waste. Headquartered in Stockholm, Sweden, Mavatar is driving the future of truly personalized, scalable healthcare across all disease areas. Mavatar.com
Tags:
